Veris Limited VRS

Moby summary of PAVmed Inc.'s Q2 2026 earnings call

PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the second quarter ended June 30, 2026.

PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the first quarter ended March 31, 2026.

Veris (VRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and year ended December 31, 2025.

We came across a bullish thesis on Veris Residential, Inc. on Colubeat Investment Desk’s Substack. In this article, we will summarize the bulls’ thesis on VRE. Veris Residential, Inc.’s share was trading at $16.84 as of February 17th. VRE’s trailing P/E was 26.40 according to Yahoo Finance. Veris Residential (NYSE:VRE) represents a compelling mispriced opportunity in the high-end […]

Veris (VRE) delivered FFO and revenue surprises of +16.35% and +1.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

A consortium including Affinius Capital and Vista Hill Partners has agreed to purchase the Northeast-focused multifamily REIT, though another bidder could emerge.

Veris Residential, Inc. (NYSE: VRE) ("Veris" or the "Company"), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") to be acquired by an investor consortium led by Affinius Capital in partnership with Vista Hill Partners (the "Investor Consortium"), in an all-cash transaction for $19.00 per share of Veris common stock (the "Transaction"), representing an implied enterprise value of $3.4 b